INVESTOR RELATIONS
KEY FIGURES
Kedrion is a leading biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as immune system deficiencies and coagulation disorders.
With a commercial presence in 100 countries, we operate through a fully integrated business model from the collection of plasma in our own centers in the United States to fractionation and production in our manufacturing facilities located in Italy, Hungary and the United States.
PRESS RELEASES
Announcement of delisting of Kedrion SpA (the “Issuer”)
Notice of confirmation of redemption condition of Kedrion SpA (the “Issuer”)
Permira Funds and the Marcucci family complete investment in Kedrion and BPL
FINANCIAL REPORTS
CONSOLIDATED FINANCIAL STATEMENTS Q1 2022
Download
CONSOLIDATED FINANCIAL STATEMENTS AS AT DECEMBER 31, 2021
Download
CONSOLIDATED FINANCIAL STATEMENTS AS AT SEPTEMBER 30, 2021
CONSOLIDATED FIRST HALF RESULTS 2021
Download
CONSOLIDATED FINANCIAL STATEMENTS Q1 2021
DOWNLOAD
CONSOLIDATED FINANCIAL STATEMENTS 2020
Download
CONSOLIDATED FIRST HALF RESULTS 2020
Download
CONTACT & EMAIL ALERTS
Subscribe to the service in order to receive our news
